Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Descriptionsort icon Status Initial Date
<a href="/venture-capital/all-companies/seahorse-bioscience-inc">Seahorse Bioscience, Inc.</a> XF instruments are the industry standard in cellular bioenergetic measurements. Private 2001 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Using T2MR to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare. Public 2006 View Profile
<a href="/venture-capital/all-companies/editas-medicine">Editas Medicine</a> Unlocking the promise of genome editing to deliver life-changing medicines. Private 2013 View Profile
<a href="/venture-capital/all-companies/black-duck-software-inc">Black Duck Software, Inc.</a> Providing the world’s only end-to-end platform for OSS Logistics. Private 2004 View Profile
<a href="/venture-capital/all-companies/ecosense-lighting%C2%AE">EcoSense Lighting®</a> Providing best-in-class LED lighting solutions for use in architectural applications. Private 2013 View Profile
<a href="/venture-capital/all-companies/selventa">Selventa</a> Pioneering the development of Systems Diagnostics (SysDx™). Private 2001 View Profile
<a href="/venture-capital/all-companies/moderna">Moderna</a> Pioneering an entirely new drug modality using messenger RNA therapeutics™. Private 2010 View Profile
<a href="/venture-capital/all-companies/joule-unlimited-inc">Joule Unlimited, Inc.</a> Pioneering a CO2-to-fuel production platform, effectively reversing combustion through the use of solar energy. Private 2007 View Profile
<a href="/venture-capital/all-companies/permeon-biologics-inc">Permeon Biologics Inc.</a> Pioneering a breakthrough class of intracellular biologics that target a broad spectrum of previously undruggable targets. Private 2011 View Profile
<a href="/venture-capital/all-companies/oasys-water-inc">Oasys Water, Inc.</a> Leading the world in the development of forward osmosis based solutions for the treatment and desalination of high saline source waters. Private 2009 View Profile
<a href="/venture-capital/all-companies/mascoma-corporation">Mascoma Corporation</a> Leading technology for the conversion of biomass to fuels and chemicals. Private 2006 View Profile
<a href="/venture-capital/all-companies/affinnova-inc">Affinnova, Inc.</a> Improving innovation and marketing success rates. Private 2000 View Profile
<a href="/venture-capital/all-companies/syros-pharmaceuticals-0">Syros Pharmaceuticals</a> Harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Private 2012 View Profile
<a href="/venture-capital/all-companies/transmedics-inc">TransMedics, Inc.</a> Extending the life saving benefits of organ transplantation to patients suffering from end-stage organ failure. Private 2010 View Profile
<a href="/venture-capital/all-companies/acceleron-pharma-inc">Acceleron Pharma, Inc.</a> Discovering, developing and commercializing novel protein therapeutics for cancer and rare diseases. Public 2004 View Profile
<a href="/venture-capital/all-companies/blend-therapeutics-inc">Blend Therapeutics Inc.</a> Discovering new classes of medicines that have unique modes of action to result in drugs with differentiated therapeutic properties. Private 2012 View Profile
<a href="/venture-capital/all-companies/eleven-biotherapeutics-inc">Eleven Biotherapeutics, Inc.</a> Discovering and developing protein therapeutics to treat diseases of the eye. Public 2008 View Profile
<a href="/venture-capital/all-companies/agios-pharmaceuticals-inc">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs to treat cancer and inborn errors of metabolism. Public 2007 View Profile
<a href="/venture-capital/all-companies/visterra-inc">Visterra, Inc.</a> Discovering and developing innovative products that will transform the prevention and treatment of infectious diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/seres-health">Seres Health</a> Discovering and developing Ecobiotic® therapeutic products to treat important diseases by targeting the underlying biology of the human microbiome. Private 2012 View Profile